the Bristol-Myers Squibb and Ono Pharmaceutical Collaboration

Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)

Retrieved on: 
Friday, January 10, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Drugs, Clinical medicine, Monoclonal antibodies, Life sciences, Antineoplastic drugs, Breakthrough therapy, Bempegaldesleukin, Bristol-Myers Squibb, Nivolumab, Nektar Therapeutics, Squib, Bristol-Myers Squibb, the Bristol-Myers Squibb and Ono Pharmaceutical Collaboration, Nektar Therapeutics

Nektar Therapeutics (Nasdaq:NKTR) and Bristol-Myers Squibb Company (NYSE:BMY) announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials.

Key Points: 
  • Nektar Therapeutics (Nasdaq:NKTR) and Bristol-Myers Squibb Company (NYSE:BMY) announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials.
  • The costs for these studies will be shared based upon the cost-sharing outlined in the terms of the original collaboration agreement.
  • Bristol-Myers Squibb and Nektar view bempeg as an important asset and IL-2 as an important target, said Fouad Namouni, M.D., head of oncology development, Bristol-Myers Squibb.
  • Withhold OPDIVO monotherapy for Grade 2 or 3 and permanently discontinue for Grade 4 or recurrent colitis upon re-initiation of OPDIVO.

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Enter Into a Clinical Collaboration Agreement to Investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as Combination Therapy in Patients With Metastatic Colorectal Cancer

Retrieved on: 
Thursday, July 18, 2019
Biotechnology, Health, Pharmaceutical, Oncology, Colorectal Cancer5, Stivarga® (regorafenib), Oncology at Bayer, Bayer, Opdivo® (nivolumab), the Bristol-Myers Squibb and Ono Pharmaceutical Collaboration, Bristol-Myers Squibb, Bristol-Myers Squibb: Advancing Oncology Research

The data seen in REGONIVO warrant further exploration of the combination of regorafenib and nivolumab in patients with colorectal cancer.

Key Points: 
  • The data seen in REGONIVO warrant further exploration of the combination of regorafenib and nivolumab in patients with colorectal cancer.
  • In metastatic colorectal cancer (mCRC), fatal hepatic failure occurred in 1.6% of patients in the STIVARGA arm and in 0.4% of patients in the placebo arm.
  • Permanently discontinue STIVARGA in patients with severe or life-threatening hemorrhage and monitor INR levels more frequently in patients receiving warfarin.
  • Toxic epidermal necrolysis occurred in 0.02% of 4518 STIVARGA-treated patients across all clinical trials of STIVARGA administered as a single agent.